EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case C-6/13 P: Appeal brought on 4 January 2013 by IDT Biologika GmbH against the judgment delivered by the General Court (Second Chamber) on 25 October 2012 in Case T-503/10 IDT Biologika GmbH v European Commission

ECLI:EU:UNKNOWN:62013CN0006

62013CN0006

January 4, 2013
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

Official Journal of the European Union

C 108/14

(Case C-6/13 P)

2013/C 108/29

Language of the case: German

Parties

Appellant: IDT Biologika GmbH (represented by: R. Gross and T. Kroupa, Rechtsanwälte)

Other party to the proceedings: European Commission

Form of order sought

Set aside the judgment of the General Court of 25 October 2012, served on the applicant/appellant by fax on 26 October 2012;

annul the decision of the Delegation of the European Union to the Republic of Serbia of 1 September 2010 rejecting the tender submitted in respect of Lot No 1 by IDT Biologika GmbH in response to the call for tenders (reference EuropeAid/129809/C/SUP/RS) for the supply of rabies vaccines to the Ministry of Agriculture, Forestry and Water Supply of the Republic of Serbia, and awarding the contract to a consortium of various firms led by ‘Bioveta a.s.’;

order the respondent to pay the costs of the proceedings.

Pleas in law and main arguments

By the judgment under appeal, the General Court erred in law in dismissing the appellant’s application.

The discretion to be exercised by the respondent European Commission in the context of the tendering procedure at issue was — from a factual and technical aspect — not exercised in such a way as to be unimpeachable.

In particular, the General Court erroneously assumed that Bioveta a.s. had, in the tendering procedure, furnished proof of the safety of the product offered by means of corresponding national authorisations, and that separate tests on primates in order to prove the non-virulence to humans of the product offered were not required.

Moreover, Bioveta a.s. has not provided proof that its vaccine is based not on the original but on a modified SAD-Bern virus strain.

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia